Cet anticorps Humanized Monoclonal détecte spécifiquement PTK7 (Cofetuzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7795145
Aperçu rapide pour Recombinant PTK7 (Cofetuzumab Biosimilar) anticorps (ABIN7795145)
Antigène
PTK7 (Cofetuzumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp PTK7 (Cofetuzumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody
Attributs du produit
What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.